Back To Press Release

Revna Biosciences receives historic Food and Drugs Authority (FDA) approval for NeuMoDx™ 96 from QIAGEN, the first in Sub-Saharan Africa

Simona-Grandits-Senior-Director-Head-of-Sales-and-Marketing-EMEA-QIAGEN.jpg

Simona Grandits, Senior Director, Head-of Sales and Marketing EMEA, QIAGEN (Source: Revna Biosciences | 1 year ago)

Image
IMG_3191.jpg

Dr. Delese Mimi Darko, the Chief Executive Officer of the FDA, Ghana (Source: Revna Biosciences | 1 year ago)

Image
REVNA.jpg

Derrick Akpalu, CEO and Co-Founder, Revna Biosciences (Source: Revna Biosciences | 1 year ago)

Image